EVALUATION OF ADJUSTED INR GOAL IN PATIENTS WITH HEARTMATE 3 LEFT VENTRICULAR ASSIST DEVICES

Predicting survival in patients receiving continuous flow left ventricular assist devices: the HeartMate II risk score.

OBJECTIVES The aim of this study was to derive and validate a model to predict survival in candidates for HeartMate II (HMII) (Thoratec, Pleasanton, California) left ventricular assist device (LVAD) support. BACKGROUND LVAD mortality risk prediction is important for candidate selection and communicating expectations to patients and clinicians. With the evolution of LVAD support, prior risk pr...

Evaluation of bend relief disconnection in patients supported by a HeartMate II left ventricular assist device.

L eft ventricular assist devices (LVADs) are an established treatment for patients with end-stage heart failure as either a bridge to cardiac transplantation 1 or as lifelong support, also known as destination therapy.) is a continuous flow device that was approved by the US Food and Drug Administration in 2008, after a pivotal trial in 133 patients awaiting transplantation. 3 More patients hav...

Left Ventricular Assist Devices.

evaluation of fat atrophy in patients with dermis fat graft of orbit by ct-scan

چکیده ندارد.

Atrial Fibrillation in Patients With Left€Ventricular Assist Devices

RESULTS Overall, AF was documented in 80 patients (32%) following LVAD placement. Before LVAD placement, 182 patients had no history of AF, whereas 67 patients had documented AF. Among these 67 patients, 56 (84%) continued to have AF following LVAD placement; 24 patients without a history of AF (13%) developed AF after LVAD placement. Patients manifesting AF after LVAD placement were more likel...